Systemic pyoderma gangrenosum responding to infliximab and adalimumab.
Pyoderma gangrenosum (PG) is frequently associated with constitutional symptoms as part of a nonspecific inflammatory response. However, extracutaneous discrete aseptic neutrophilic infiltrates are extremely rare. We report a patient with idiopathic PG with splenic and psoas muscle involvement. His disease was extremely aggressive and was unresponsive to conventional immunosuppressive therapy. His cutaneous and extracutaneous PG cleared with infliximab and adalimumab.
Hubbard
V G
VG
Department of Dermatology, Royal London Hospital, Whitechapel Road, London E1 1BB, UK. vghubbard@yahoo.co.uk
Friedmann
A C
AC
Goldsmith
P
P
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D000069285:Infliximab; D007868:Leg Dermatoses / Q000188:drug therapy; D008297:Male; D017511:Pyoderma Gangrenosum / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D000069285:Infliximab; D000068879:Adalimumab